Platform vs. Add-On: What Type of Buyer Does Your Dermatology Practice Qualify For

The question comes up regularly…. “Can I be a platform PE investment, or is my dermatology practice better suited to be acquired by an existing strategic MSO?”

It’s a very well-educated question. However, we often find that the differences between the two buyer types are often misunderstood, and in many cases, the factors that figure into what opportunities may present themselves to your practice extend far beyond the generally understood “size” conversation.

Understanding the size of your practice, the different buyer types active in your geography, and the operational systems inside your business are the keys to finding the answers to commonly asked questions about the sales process. Answer those, and you’ll understand what your dermatology practice is worth and who the prospective buyers are.

What Buyers Mean When They Talk About “Size”

The size of your dermatology practice isn’t just about your revenue or number of locations.

When buyers evaluate whether your practice qualifies as a platform or an acquisition, they’re assessing multiple dimensions simultaneously:

EBITDA is the foundation. Unlike traditional doctor-to-doctor transactions that value practices based on a percentage of collections, institutional buyers focus on EBITDA multiples. Dermatology practices generating $3M to $5M+ in EBITDA typically enter platform territory. Practices in the $2-3M EBITDA range can attract interest from both platform and add-on buyers, though the scalability of your current business model plays an important role in the buyer pool.

Geographic footprint tells a growth story. Your physical presence matters significantly. Dermatology practice buyers look for one of three scenarios: density within a single metro area that dominates local market share, regional coverage across a state or multiple states that provides diversification, or untapped de novo expansion potential in your existing markets. The right footprint depends on the buyer’s growth strategy. Some prioritize geographic density while others seek to scale their dermatology MSO regionally.

Be your own MSO. Some growth-oriented strategic groups will look to jumpstart a “platform” in a new geography with a smaller well-positioned investment. This technically wouldn’t qualify as a “platform” investment, but it can provide a solid value proposition for the right owner. While this may not be a good fit for everyone, in many cases, it can allow you to have your own sub-group inside a broader, well-established infrastructure. For a younger, entrepreneurial dermatology practice owner, this can provide an optimal balance of growth opportunity and risk mitigation.

Platform Deals in Dermatology: Built to Scale

Platform transactions are fundamentally different animals. Buyers are investing in a foundation upon which to build a regional or national dermatology group.

Infrastructure is ready for scaling. In stepping back from an acquisition strategy, it’s important to understand that many private equity groups are interested in the healthcare space. However, they may not have the expertise to actually run a healthcare business. As such, it’s critically important for an investor that a platform investment include a scaled management infrastructure. This can take on a lot of different looks depending upon the makeup of the group in question; however, in general, some semblance of direct practice operational management, HR, Marketing, and leadership should either be in development or be a part of the long-term growth strategy.

Provider bench reduces key man risk. For platform consideration, your dermatology practice should have a strong multi-provider bench with a robust team of physician assistants and nurse practitioners. This depth signals to buyers that the practice can continue thriving and scaling beyond any single provider. For smaller dermatology practices with single providers, we often see the buyer landscape limited to an MSO acquisition. Key man risk is one of the most prevalent considerations any buyer has, and understanding that is critical when walking into a marketed sales process.

Procedure mix and margins matter. Service lines tell buyers about your future profitability. Medical aesthetics capabilities are particularly attractive in today’s dermatology market, as are strong medical dermatology margins. Practices with EBITDA margins of 25%+ command premium valuations, while 15-20% can still be very competitive. Margins below 15% raise concerns about operational efficiency and competitive positioning. This is also an indicator of practice size.

The valuation premium is substantial. Platform deals typically achieve multiples of 8-10X EBITDA or higher. Why? Because buyers are valuing not just your current earnings but your practice’s capacity to serve as an acquisition and integration engine. Platform dermatology deals will also require you to roll over a portion of your proceeds into equity in the new entity to ensure that all parties are “rowing in the same direction”.  This “second bite of the apple” opportunity can be lucrative when the platform successfully executes its growth strategy and sells to a larger buyer down the road.

You’re signing up for the journey. Platform deals come with longer post-sale employment commitments, typically 7+ years. Platform sellers are usually entrepreneurial dermatology practice owners who are energized by the opportunity to scale their practice with institutional capital and resources behind them. You’ll likely maintain significant operational involvement and decision-making authority, especially in the early innings.

Add-On / MSO Dermatology Deals: Strategic Fit & Integration

Add-on transactions serve a different purpose. An existing dermatology platform or group is acquiring your practice to expand its geographic reach, add provider capacity, or capture additional market share in your region. They have the systems in place to expand the margins in your business and provide greater support for your team.

Valuations vary widely based on strategic value. Dermatology practices partnering with MSOs can see a wide range of multiples based on their practice’s attributes, anywhere from 4X – 10X+ EBITDA.

Employment commitments are typically shorter. Add-on deals usually require 3-5 year post-sale employment agreements, though this is negotiable. These structures often appeal to owners looking to de-risk their personal balance sheet, monetize their business, reduce operational burdens, and create a clear pathway to retirement.

Why You Should Consider a Dermatology Practice Assessment

Many large practice owners underestimate their dermatology practice’s exit options because they’re too close to their own operations and are emotionally invested in the business as a whole. They miss the nuances that buyers weigh heavily. They overlook infrastructure gaps that disqualify them from platform consideration. Or they assume they’re only add-on material when strategic positioning could unlock platform-level valuations.

We offer complimentary dermatology practice assessments with no obligation. We evaluate your practice through the lens of both platform and add-on buyers, help you understand your realistic options, and identify specific improvements that could move you into a higher valuation tier.

You wouldn’t expect us to walk into your practice and start prescribing medications or performing procedures. In the same way, we know where our expertise lies. TUSK does one thing, and we do it at the highest level, every day.

No pressure. No obligation. Just clarity on selling your dermatology practice.